|
Published by: BCC Research
Published: Aug. 1, 2003 - 189 Pages
Table of Contents
Introduction
Study Goals And Objectives
Reasons For Study
Scope Of Study
Methodology And Information Sources
Analyst Credentials
Related Bcc Reports
Bcc Online Services
Internet
Disclaimer
Executive Summary
Summary Table:
Global And U.S. Total Market For Central Nervous System Psychotherapeutic Drugs, Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Summary Figure:
Global And U.S. Market For Central Nervous System Psychotherapeutic Drugs, Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Industry Overview
Historical Perspective Of The Mental Health Industry
Introduction To The Nervous System And Brain
Blood-Brain Barrier
Mental Health Disorders
Alzheimer’s Disease
Table 1 Major Causes Of Progressive Dementia (%)
Table 2 Pharmacologic Management Of Alzheimer’s Disease
Anxiety Disorders
Generalized Anxiety Disorder
Panic Disorder
Post-Traumatic Stress Disorder
Specific And Social Phobias
Table 3 Clinical Names For Common Phobias
Attention Deficit Hyperactivity Disorder
Bipolar Disorder
Bipolar I Disorder
Bipolar Ii Disorder
Cyclothymic Disorder
Borderline Personality Disorder
Depression
Eating Disorders
Anorexia Nervosa
Bulimia Nervosa
Obsessive-Compulsive Disorder
Schizophrenia
Sleep Disorders
Insomnia
Narcolepsy
Restless Legs Syndrome
Parasomnia
Substance Abuse-Related Disorders
Alcohol Abuse
Drug Abuse
Demographics
Table 4 Estimated Incidence/Prevalence Of Conditions, 2000 (Thousands)
Prescribing Trends
Pediatric And Adolescent Use
Preschooler Use
Pharmaceutical Testing In Children
Cost
Reimbursement Issues
Legislative Actions
Elderly Impact
Psychiatric Pharmacogenetics
Patent Issues And Generic Participation
Table 5 Patent Expiration For Selected Prescription Psychotherapeutics 2002
Compliance Issues
Internet Addiction—Fact Or Fiction
Genetic Link To Multiple Disorders
Psychiatric Diseases On The Rise
Mental Health Agenda Setting—Another View
Healthcare Reform
Prescription Central Nervous System Depressants And Antianxiety Drugs
Overview
Marketed Products
Barbiturates
Benzodiazepines
Miscellaneous Central Nervous System Depressants And Antianxiety Drugs
Market Size And Forecast
Table 6 Market Size Of Global Central Nervous System Depressants And Antianxiety Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Figure 1 Market Size Of Global Central Nervous System Depressants And Antianxiety Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Table 7 Market Size Of U.S. Central Nervous System Depressants And Antianxiety Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Figure 2 Market Size Of U.S. Central Nervous System Depressants And Antianxiety Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Table 8 Geographical Distribution Of Global Central Nervous System Depressants And Antianxiety Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 (%)
Figure 3 Geographical Distribution Of Global Central Nervous System Depressants And Antianxiety Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 (%)
Products In The Pipeline
Table 9 Prescription Central Nervous System Depressants And Antianxiety Drugs In Development 2002
Competitive Analysis
Table 10 Global Central Nervous System Depressants And Antianxiety Drug Manufacturer Market Share By Revenues, 2002
Figure 4 Central Nervous System Depressants And Antianxiety Drug Manufacturer Percentage Market Share By Revenues, 2002
Prescription Central Nervous System Antidepressant Drugs
Overview
Marketed Products
Monoamine Oxidase Inhibitors
Selective Serotonin Reuptake Inhibitors
Tricyclic Antidepressants
Miscellaneous Antidepressants
Market Size And Forecast
Table 11 Market Size Of Global Central Nervous System Antidepressant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Figure 5 Market Size Of Global Central Nervous System Antidepressant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Table 12 Market Size Of U.S. Central Nervous System Antidepressant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Figure 6 Market Size Of U.S. Central Nervous System Antidepressant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Table 13 Geographical Distribution Of Global Central Nervous System Antidepressant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 (%)
Figure 7 Geographical Distribution Of Global Central Nervous System Antidepressant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 (%)
Products In The Pipeline
Table 14 Prescription Central Nervous System Antidepressant Drugs In Development 2002
Competitive Analysis
Table 15 Central Nervous System Antidepressant Drug Manufacturer Market Share By Revenues, 2002
Figure 8 Central Nervous System Antidepressant Drug Manufacturer Percent Market Share By Revenues, 2002 (%)
Prescription Central Nervous System Antimanic Drugs
Overview
Marketed Products
Lithium
Miscellaneous Antimanic Drugs
Market Size And Forecast
Table 16 Market Size Of Global Central Nervous System Antimanic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Figure 9 Market Size Of Global Central Nervous System Antimanic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Table 17 Market Size Of U.S. Central Nervous System Antimanic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Figure 10 Market Size Of U.S. Central Nervous System Antimanic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Table 18 Geographical Distribution Of Global Central Nervous System Antimanic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 (%)
Figure 11 Geographical Distribution Of Global Central Nervous System Antimanic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 (%)
Products In The Pipeline
Table 19 Prescription Central Nervous System Antimanic Drugs In Development 2002
Competitive Analysis
Table 20 Central Nervous System Antimanic Drug Manufacturer Market Share By Revenues, 2002
Figure 12 Central Nervous System Antimanic Drug Manufacturer Percent Market Share By Revenues, 2002
Prescription Central Nervous System Antipsychotic Drugs
Overview
Marketed Products
Phenothiazines And Combinations
Miscellaneous Antipsychotic Agents
Market Size And Forecast
Table 21 Market Size Of Global Central Nervous System Antipsychotic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Figure 13 Market Size Of Global Central Nervous System Antipsychotic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Table 22 Market Size Of U.S. Central Nervous System Antipsychotic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Figure 14 Market Size Of U.S. Central Nervous System Antipsychotic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Table 23 Geographical Distribution Of Global Central Nervous System Antipsychotic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 (%)
Figure 15 Geographical Distribution Of Global Central Nervous System Antipsychotic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 (%)
Products In The Pipeline
Table 24 Prescription Central Nervous System Antipsychotic Drugs In Development, 2002
Competitive Analysis
Table 25 Central Nervous System Antipsychotic Drug Manufacturer Market Share By Revenues, 2002
Figure 16 Central Nervous System Antipsychotic Drug Manufacturer Percent Market Share By Revenues, 2002
Prescription Central Nervous System Stimulant Drugs
Overview
Marketed Products
Amphetamines
Miscellaneous Central Nervous System Stimulants
Market Size And Forecast
Table 26 Market Size Of Global Central Nervous System Stimulant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Figure 17 Market Size Of Global Central Nervous System Stimulant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Table 27 Market Size Of U.S. Central Nervous System Stimulant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Figure 18 Market Size Of U.S. Central Nervous System Stimulant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Table 28 Geographical Distribution Of Global Central Nervous System Stimulant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 (%)
Figure 19 Geographical Distribution Of Global Central Nervous System Stimulant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 (%)
Products In The Pipeline
Table 29 Prescription Central Nervous System Stimulant Drugs In Development, 2002
Competitive Analysis
Table 30 Central Nervous System Stimulant Drug Manufacturer Market Share By Revenues, 2002
Figure 20 Central Nervous System Stimulant Drug Manufacturer Percent Market Share By Revenues, 2002 (%)
Prescription Central Nervous System Cholinesterase Inhibitor And Miscellaneous Alzheimer Treatment Drugs
Overview
Marketed Products
Market Size And Forecast
Table 31 Market Size Of Global Central Nervous System Cholinesterase Inhibitor And Miscellaneous Alzheimer Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Figure 21 Market Size Of Global Central Nervous System Cholinesterase Inhibitor And Miscellaneous Alzheimer Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Table 32 Market Size Of U.S. Central Nervous System Cholinesterase Inhibitor And Miscellaneous Alzheimer Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Figure 22 Market Size Of U.S. Central Nervous System Cholinesterase Inhibitor And Miscellaneous Alzheimer Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Table 33 Geographical Distribution Of Global Central Nervous System Cholinesterase Inhibitor And Miscellaneous Alzheimer’s Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 (%)
Figure 23 Geographical Distribution Of Global Central Nervous System Cholinesterase Inhibitor And Miscellaneous Alzheimer’s Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 (%)
Products In The Pipeline
Table 34 Prescription Central Nervous System Cholinesterase Inhibitors And Alzheimer Treatment Drugs In Development, 2002
Competitive Analysis
Table 35 Central Nervous System Cholinesterase Inhibitor And Miscellaneous Alzheimer Treatment Drug Manufacturer Market Share By Revenues, 2002
Figure 24 Central Nervous System Cholinesterase Inhibitor And Miscellaneous Alzheimer Treatment Drug Manufacturer Percent Market Share By Revenues, 2002 (%)
Prescription Central Nervous System Substance Abuse Treatment Drugs
Overview
Marketed Products
Market Size And Forecast
Table 36 Market Size Of Global Central Nervous System Substance Abuse Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Figure 25 Market Size Of Global Central Nervous System Substance Abuse Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Table 37 Market Size Of U.S. Central Nervous System Substance Abuse Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Figure 26 Market Size Of U.S. Central Nervous System Substance Abuse Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Table 38 Geographical Distribution Of Global Central Nervous System Substance Abuse Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 (%)
Figure 27 Geographical Distribution Of Global Central Nervous System Substance Abuse Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 (%)
Products In The Pipeline
Table 39 Prescription Central Nervous System Substance Abuse Treatment Drugs In Development, 2002
Competitive Analysis
Table 40 Central Nervous System Substance Abuse Drug Manufacturer Market Share By Revenues, 2002
Figure 28 Central Nervous System Substance Abuse Drug Manufacturer Percent Market Share By Revenues, 2002 (%)
Total Market Summary
Industry Structure
Global Market For Psychotherapeutic Drugs
Table 41 Global Market For Central Nervous System Psychotherapeutic Drugs, Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Figure 29 Global Market For Central Nervous System Psychotherapeutic Drugs, Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Global Market Percentage By Product Type
Table 42 Global Market Percent For Central Nervous System Psychotherapeutic Drugs By Category, 2002
U.S. Market For Psychotherapeutic Drugs
Table 43 U.S. Market For Central Nervous System Psychotherapeutic Drugs, Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Figure 30 U.S. Market For Central Nervous System Psychotherapeutic Drugs, Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
U.S. Market Percentage By Product Type
Table 44 U.S. Market Percent For Central Nervous System Psychotherapeutic Drugs By Category, Through 2007
Total Competitive Structure And Market Share
Table 45 Total Central Nervous System Psychotherapeutic Drug Comeptitive Market, 2002
Figure 31 Total Central Nervous System Psychotherapeutic Drug Comeptitive Market, 2002 (%)
Industry Participants By Product Type
Table 46 Central Nervous System Psychotherapeutic Drug Manufacturers By Product Type, 2002
Competitive Strategies Based On Products
Company Profiles
Abbott Laboratories
Astrazeneca Plc
Bristol-Myers Squibb Company
Eli Lilly & Company
Forest Laboratories, Inc.
Glaxosmithkline Plc
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Novartis International Ag
Organon International, Inc.
Pfizer, Inc.
Pharmacia Corp.
Sanofi-Synthelabo
Shire Pharmaceuticals Group Plc
Wyeth
Appendix
List Of Companies
List Of Tables
Summary Table:
Global And U.S. Total Market For Central Nervous System Psychotherapeutic Drugs, Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Table 1 Major Causes Of Progressive Dementia (%)
Table 2 Pharmacologic Management Of Alzheimer’s Disease
Table 3 Clinical Names For Common Phobias
Table 4 Estimated Incidence/Prevalence Of Conditions, 2000 (Thousands)
Table 5 Patent Expiration For Selected Prescription Psychotherapeutics 2002
Table 6 Market Size Of Global Central Nervous System Depressants And Antianxiety Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Table 7 Market Size Of U.S. Central Nervous System Depressants And Antianxiety Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Table 8 Geographical Distribution Of Global Central Nervous System Depressants And Antianxiety Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 (%)
Table 9 Prescription Central Nervous System Depressants And Antianxiety Drugs In Development 2002
Table 10 Global Central Nervous System Depressants And Antianxiety Drug Manufacturer Market Share By Revenues, 2002
Table 11 Market Size Of Global Central Nervous System Antidepressant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Table 12 Market Size Of U.S. Central Nervous System Antidepressant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Table 13 Geographical Distribution Of Global Central Nervous System Antidepressant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 (%)
Table 14 Prescription Central Nervous System Antidepressant Drugs In Development 2002
Table 15 Central Nervous System Antidepressant Drug Manufacturer Market Share By Revenues, 2002
Table 16 Market Size Of Global Central Nervous System Antimanic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Table 17 Market Size Of U.S. Central Nervous System Antimanic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Table 18 Geographical Distribution Of Global Central Nervous System Antimanic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 (%)
Table 19 Prescription Central Nervous System Antimanic Drugs In Development 2002
Table 20 Central Nervous System Antimanic Drug Manufacturer Market Share By Revenues, 2002
Table 21 Market Size Of Global Central Nervous System Antipsychotic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Table 22 Market Size Of U.S. Central Nervous System Antipsychotic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Table 23 Geographical Distribution Of Global Central Nervous System Antipsychotic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 (%)
Table 24 Prescription Central Nervous System Antipsychotic Drugs In Development, 2002
Table 25 Central Nervous System Antipsychotic Drug Manufacturer Market Share By Revenues, 2002
Table 26 Market Size Of Global Central Nervous System Stimulant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Table 27 Market Size Of U.S. Central Nervous System Stimulant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Table 28 Geographical Distribution Of Global Central Nervous System Stimulant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 (%)
Table 29 Prescription Central Nervous System Stimulant Drugs In Development, 2002
Table 30 Central Nervous System Stimulant Drug Manufacturer Market Share By Revenues, 2002
Table 31 Market Size Of Global Central Nervous System Cholinesterase Inhibitor And Miscellaneous Alzheimer Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Table 32 Market Size Of U.S. Central Nervous System Cholinesterase Inhibitor And Miscellaneous Alzheimer Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Table 33 Geographical Distribution Of Global Central Nervous System Cholinesterase Inhibitor And Miscellaneous Alzheimer’s Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 (%)
Table 34 Prescription Central Nervous System Cholinesterase Inhibitors And Alzheimer Treatment Drugs In Development, 2002
Table 35 Central Nervous System Cholinesterase Inhibitor And Miscellaneous Alzheimer Treatment Drug Manufacturer Market Share By Revenues, 2002
Table 36 Market Size Of Global Central Nervous System Substance Abuse Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Table 37 Market Size Of U.S. Central Nervous System Substance Abuse Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Table 38 Geographical Distribution Of Global Central Nervous System Substance Abuse Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 (%)
Table 39 Prescription Central Nervous System Substance Abuse Treatment Drugs In Development, 2002
Table 40 Central Nervous System Substance Abuse Drug Manufacturer Market Share By Revenues, 2002
Table 41 Global Market For Central Nervous System Psychotherapeutic Drugs, Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Table 42 Global Market Percent For Central Nervous System Psychotherapeutic Drugs By Category, 2002
Table 43 U.S. Market For Central Nervous System Psychotherapeutic Drugs, Revenues At U.S. Manufacturers’ Sales Levels, Through 2007 ($ Millions)
Table 44 U.S. Market Percent For Central Nervous System Psychotherapeutic Drugs By Category, Through 2007
Table 45 Total Central Nervous System Psychotherapeutic Drug Comeptitive Market, 2002
Table 46 Central Nervous System Psychotherapeutic Drug Manufacturers By Product Type, 2002
List Of Figures
Summary Figure:
Global And U.S. Market For Central Nervous System Psychotherapeutic Drugs, Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Figure 1 Market Size Of Global Central Nervous System Depressants And Antianxiety Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Figure 2 Market Size Of U.S. Central Nervous System Depressants And Antianxiety Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Figure 3 Geographical Distribution Of Global Central Nervous System Depressants And Antianxiety Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 (%)
Figure 4 Central Nervous System Depressants And Antianxiety Drug Manufacturer Percentage Market Share By Revenues, 2002
Figure 5 Market Size Of Global Central Nervous System Antidepressant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Figure 6 Market Size Of U.S. Central Nervous System Antidepressant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Figure 7 Geographical Distribution Of Global Central Nervous System Antidepressant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 (%)
Figure 8 Central Nervous System Antidepressant Drug Manufacturer Percent Market Share By Revenues, 2002 (%)
Figure 9 Market Size Of Global Central Nervous System Antimanic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Figure 10 Market Size Of U.S. Central Nervous System Antimanic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Figure 11 Geographical Distribution Of Global Central Nervous System Antimanic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 (%)
Figure 12 Central Nervous System Antimanic Drug Manufacturer Percent Market Share By Revenues, 2002
Figure 13 Market Size Of Global Central Nervous System Antipsychotic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Figure 14 Market Size Of U.S. Central Nervous System Antipsychotic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Figure 15 Geographical Distribution Of Global Central Nervous System Antipsychotic Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 (%)
Figure 16 Central Nervous System Antipsychotic Drug Manufacturer Percent Market Share By Revenues, 2002
Figure 17 Market Size Of Global Central Nervous System Stimulant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Figure 18 Market Size Of U.S. Central Nervous System Stimulant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Figure 19 Geographical Distribution Of Global Central Nervous System Stimulant Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 (%)
Figure 20 Central Nervous System Stimulant Drug Manufacturer Percent Market Share By Revenues, 2002 (%)
Figure 21 Market Size Of Global Central Nervous System Cholinesterase Inhibitor And Miscellaneous Alzheimer Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Figure 22 Market Size Of U.S. Central Nervous System Cholinesterase Inhibitor And Miscellaneous Alzheimer Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Figure 23 Geographical Distribution Of Global Central Nervous System Cholinesterase Inhibitor And Miscellaneous Alzheimer’s Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 (%)
Figure 24 Central Nervous System Cholinesterase Inhibitor And Miscellaneous Alzheimer Treatment Drug Manufacturer Percent Market Share By Revenues, 2002 (%)
Figure 25 Market Size Of Global Central Nervous System Substance Abuse Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Figure 26 Market Size Of U.S. Central Nervous System Substance Abuse Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Figure 27 Geographical Distribution Of Global Central Nervous System Substance Abuse Treatment Drugs By Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 (%)
Figure 28 Central Nervous System Substance Abuse Drug Manufacturer Percent Market Share By Revenues, 2002 (%)
Figure 29 Global Market For Central Nervous System Psychotherapeutic Drugs, Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Figure 30 U.S. Market For Central Nervous System Psychotherapeutic Drugs, Revenues At U.S. Manufacturers’ Sales Levels, 2000-2007 ($ Millions)
Figure 31 Total Central Nervous System Psychotherapeutic Drug Comeptitive Market, 2002 (%)
Abstract STUDY GOAL AND OBJECTIVES
The objectives of the study are to present a comprehensive look at disorders that affect the mind. An overall discussion of mental health is presented along with an in-depth discovery of the various diseases and disorders that present significant problems for individuals and society. Markets are divided according to drug type because several products are used in many different disorders.
REASONS FOR DOING THIS STUDY
This study is presented to highlight the exciting area of mental health. Because in-depth study of the workings of the brain is a fairly new area of intense study, there are new and changing theories. The discovery of new mechanisms and chemicals in the brain has provided additional avenues for research and development of products that may alter the course of the diseases or modify the outcome. This study analyzes the current psychotherapeutics and explores the new psychotherapeutics that are in the pipeline to treat mental disorders. The study also addresses the many and varied issues and trends affecting the market. Manufacturers have increased the pace of research and development for psychotherapeutic products fueled by demand for new and better compounds to treat psychological disorders. Because of the rapidly evolving climate of psychological disorders and the increasing knowledge of the workings of the brain, manufacturers of psychotherapeutics must remain ever vigilant of the changing environment and strive to keep abreast of current and potential opportunities.
SCOPE OF STUDY
The report is designed to be a comprehensive business tool to provide an in-depth look at the fascinating world of mental health. The geographic scope of the report is global with an emphasis on the United States. The report identifies the different disorders in mental health; gives an explanation of the disorders; cites incidence; identifies specific drug types; presents current treatments, market size and market participants; and presents potential treatments in research and development. The report describes the industry in detail, its relationship to the healthcare industry and healthcare reform, its participants, and its trends for the future. Within the Market for Prescription Psychotherapeutic Drugs, the following markets are evaluated:
Prescription Central Nervous System Depressants and Antianxiety Drugs
Prescription Central Nervous System Antidepressant Drugs
Prescription Central Nervous System Antimanic Drugs
Prescription Central Nervous System Antipsychotic Drugs
Prescription Central Nervous System Stimulant Drugs
Prescription Central Nervous System Cholinesterase
Inhibitor and Miscellaneous Alzheimer Treatment Drugs
Prescription Central Nervous System Substance Abuse
Treatment Drugs
All markets are further broken down into specific types of products that are discussed in detail, measuring current and potential market size, identifying current and potential market drivers, forecasting for 2002 and 2007, assessing current and potential competitors and identifying current competitor market shares.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
